Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

作者：van der Helm L H; Veeger N J G M; van Marwijk Kooy M; Beeker A; de Weerdt O; de Groot M; Alhan C; Hoogendoorn M; Laterveer L; van de Loosdrecht A A; Koedam J; Vellenga E; Huls G^*

来源：Leukemia Research, 2013, 37(8): 877-882.

DOI：10.1016/j.leukres.2013.03.022

• Acute myeloid leukemia
• Older age
• Azacitidine
• Bone marrow blast count
• Predictors

The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with %26gt;= 30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score %26gt;= 2, and white blood cell count %26gt;= 15x10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). %26lt;br%26gt;In conclusion, administration of azacitidine is effective in AML patients with 20-30% and %26gt;30% BM blasts.

• 出版日期2013-8